Select therapeutic use:
Indications for ADENOSCAN:
Adjunct to thallium-201 myocardial perfusion scintigraphy in patients unable to undergo adequate exercise stress.
Give peripherally as a continuous IV infusion. ≥18yrs: 140mcg/kg/min over 6 mins for a total dose of 0.84mg/kg. Infusion rate (mL/min)= 0.140 (mg/kg/min) x total body weight (kg)/adenosine conc. (3mg/mL). See full labeling.
<18yrs: not established.
2nd- or 3rd-degree AV block or sinus node disease (eg, sick sinus syndrome, symptomatic bradycardia), unless paced. Bronchoconstructive or bronchospastic disease (eg, asthma).
Have resuscitative measures available. Increased risk of cardiovascular events in patients with acute MI, unstable angina, or cardiovascular instability; avoid use. Pre-existing 1st-degree AV block or bundle branch block. Discontinue if persistent or symptomatic high-grade AV block or hypotension occurs. Autonomic dysfunction. Stenotic valvular heart disease. Pericarditis or pericardial effusions. Stenotic carotid artery disease with cerebrovascular insufficiency. Hypovolemia. Obstructive lung disease (eg, emphysema, bronchitis). Discontinue if severe respiratory difficulties occur. Elderly. Pregnancy (Cat.C). Nursing mothers.
May be potentiated by β-blockers, cardiac glycosides, calcium channel blockers; use caution. Increased risk of seizures with concomitant methylxanthines (eg, caffeine, aminophylline, theophylline): not recommended. Potentiated by dipyridamole.
Flushing, chest discomfort, dyspnea, headache, throat/neck/jaw discomfort, GI discomfort, lightheadedness/dizziness; cardiac arrest, sustained ventricular tachycardia, MI, bronchoconstriction, hypo- or hypertension, cerebrovascular accident, convulsive seizures, atrial fibrillation.
Single-use vials (20mL, 30mL)—10